Galderma Group AG
🇨🇭Switzerland
Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep
Phase 4
Completed
- Conditions
- Nasolabial FoldsWrinkles
- Interventions
- Device: Emervel DeepDevice: Emervel Classic
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 20
- Registration Number
- NCT02672644
- Locations
- 🇨🇦
Arthur Swift Research Inc., Montreal, Quebec, Canada
Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand
Not Applicable
Completed
- Conditions
- Volume Deficit in the Hand
- Interventions
- Device: Restylane Lyft with Lidocaine
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 92
- Registration Number
- NCT02650921
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
Completed
- Conditions
- Rosacea
- Interventions
- Other: Mirvaso® / Onreltea TM
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 301
- Registration Number
- NCT02637232
- Locations
- 🇨🇦
Investigator site 1, Hamilton, Canada
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
Phase 4
Completed
- Conditions
- Rosacea
- Interventions
- Other: CD07805/47 (Br) placebo gelOther: CD5024 (IVM) placebo cream
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 190
- Registration Number
- NCT02616250
Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
Not Applicable
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Other: Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body washOther: Cetaphil® Restoraderm® body wash
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 120
- Registration Number
- NCT02589392
- Locations
- 🇵🇭
Jose R. Reyes Memorial Medical Center, Manila, Philippines
🇨🇳Department of Dermatology /Shenzhen Children's hospital, Shenzhen, Guangdong, China
🇨🇳Hunan Children's Hospital, Hunan, Hunan, China
Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris
Phase 4
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Other: Dermotivin® Soft Liquid cleanserOther: Cetaphil® Dermacontrol Moisturizer SPF30
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT02589405
- Locations
- 🇩🇪
EGBERT Mi-Ran, Münster, Germany
Perception of Facial Expressions Following Correction of Wrinkles and Folds
Phase 4
Completed
- Conditions
- Wrinkles and Folds in Lower Face
- Interventions
- Device: Emervel Classic LidocaineDevice: Emervel Deep Lidocaine
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 63
- Registration Number
- NCT02573337
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: CD5789 (trifarotene) 50μg/g creamDrug: Placebo cream
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1208
- Registration Number
- NCT02566369
- Locations
- 🇭🇺
Galderma Investigational Site (5254), Nyíregyháza, Hungary
🇵🇷Galderma Investigational Site (8594), Caguas, Puerto Rico
🇺🇸Galderma Investigational Site (8143), Miami, Florida, United States
Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population
Not Applicable
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Device: RestylaneDevice: Perlane
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 100
- Registration Number
- NCT02565784
- Locations
- 🇨🇳
Galderma Research Site, Taipei City, Taiwan
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Placebo CreamDrug: CD5789 (trifarotene) 50µg/g Cream
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1212
- Registration Number
- NCT02556788
- Locations
- 🇵🇱
Galderma investigational Site, Warszawa, Poland
🇪🇸Galderma Investigational site, Madrid, Spain
🇺🇸Galderma Invetsigational site, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath